Home > Health Conditions > Diabetes > Onglyza (saxagliptin)

Onglyza (saxagliptin)

Related Topics:

• Actos (pioglitazone HCl) / Amaryl (glimepiride) / Avandia (rosiglitazone) / Byetta (exenatide) / Diabeta, Micronase (glyburide) / Farxiga (dapagliflozin) / Glucophage (metformin) / insulin / Invokana (canagliflozin) / Januvia (sitagliptin) / Jardiance (empagliflozin) / Lantus (glargine) / Onglyza (saxagliptin) / Prandin™ (repaglinide) / Precose (acarbose) / Rezulin (troglitazone) / Starlix® (nateglinide) / Symlin (pramlintide acetate) / Victoza (liraglutide)

News & Research:

• Diabetes Drugs Tied to Less Amyloid, Slowed Cognitive Decline in Alzheimer's - Medscape, 8/11/21 - "Compared to the group not taking a DPP-4 inhibitor, those taking these agents had significantly lower global SUVRs (1.33 vs 1.41; P = .001). These patients also had significantly lower regional Aβ SUVRs (frontal:1.33 vs 1.41; lateral parietal: 1.34 vs 1.42; lateral temporal: 1.33 vs 1.41; and anterior cingulate/posterior cingulate cortices: 1.43 vs 1.53 ... In addition, those taking DPP-4 inhibitors had lower Aβ burden globally and in two regional cortices ― the lateral parietal and lateral temporal ― compared to the nondiabetes group"
• FDA Warns of Heart Failure Risk With Two Diabetes Drugs - Medscape, 4/5/16 - "Health care professionals should consider discontinuing medications containing saxagliptin and alogliptin in patients who develop heart failure and monitor their diabetes control ... In the saxagliptin trial, which included 16,492 patients with type 2 diabetes and established cardiovascular disease or who were at high risk for cardiovascular disease, there was no overall risk for cardiovascular events, but there was a 27% increase (3.5% vs. 2.8%) in the rate of the first event of hospitalization for heart failure and a potential increased risk for all-cause mortality"
• Metformin vs. Sulfonylureas for Diabetes - WebMD, 12/4/09 - "Researchers reported that diabetes patients who used sulfonylureas had a higher risk of death from all causes and a higher risk of heart failure than diabetes patients who used the most widely prescribed diabetes drug, metformin ... Compared with metformin, also known as Glucophage, single-drug treatment with first- and second-generation sulfonylureas was associated with up to a 61% increased risk for death. Users of second-generation sulfonylureas had up to a 30% higher risk for congestive heart failure ... Patients treated with Actos or Avandia did not appear to have a greater risk for heart attacks than those treated with metformin"
• FDA Approves Saxagliptin for Type 2 Diabetes - Doctor's Guide, 7/31/09 - "Although saxagliptin was not associated with an increased risk for cardiovascular events in patients who were mainly at low risk for these events, the FDA is requiring a post-market study that will specifically evaluate cardiovascular safety in a higher risk population"